Gland Pharma Limited — Board Meeting, 10-08-2026: Outcome of Board Meeting
10-08-2026 | 04:19 pm
10-08-2026 | 04:19 pm
Gland Pharma's board approved strong Q1FY27 consolidated financial results. Revenue surged 20% YoY to ₹1,800.3 Cr, while Profit After Tax jumped 47% YoY to ₹317 Cr. CDMO & B2B businesses drove growth, reflecting successful strategy execution.
No comments yet. Be the first to comment!
